Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 3, 2012, Pages 245-252

  Cressey, Tim R ^a,b,c   Stek, Alice ^d   Capparelli, Edmund ^e   Bowonwatanuwong, Chureeratana ^f   Prommas, Sinart ^g   Sirivatanapa, Pannee ^a   Yuthavisuthi, Prapap ^h   Neungton, Chanon ⁱ   Huo, Yanling ^b   Smith, Elizabeth ^j   Best, Brookie M ^e   Mirochnick, Mark ^k  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f CHONBURI HOSPITAL   (Thailand)

^g BHUMIBOL ADULYADEJ HOSPITAL   (Thailand)

^h PRAPOKKLAO HOSPITAL   (Thailand)

ⁱ MAHIDOL UNIVERSITY   (Thailand)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^k BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Efavirenz; HIV; Pharmacokinetics; Pregnancy; Prevention of mother to child transmission of HIV

Indexed keywords

EFAVIRENZ;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MATERNAL BLOOD; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; PUERPERIUM; THIRD TRIMESTER PREGNANCY; TIME TO MAXIMUM PLASMA CONCENTRATION; UMBILICAL CORD BLOOD;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; BENZOXAZINES; COHORT STUDIES; FEMALE; FETAL BLOOD; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY TRIMESTER, THIRD; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84859758788     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31823ff052     Document Type: Article

References (24)

1. De Santis M, Carducci B, De Santis L, et al. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med. 2002;162: 355. (Pubitemid 34127415)
2. Fundaro C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS. 2002;16: 299-300. (Pubitemid 34118582)
3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents Developed by the DHHS panel on antiretroviral guidelines for adults and adolescents-A Working Group of the Office of AIDS Research Advisory Council. Available at: http: //aidsinfonihgov. Accessed January 10, 2011.
4. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003;306: 287-300. (Pubitemid 36734384)
5. Tracy TS, Venkataramanan R, Glover DD, et al. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol. 2005;192: 633-639. (Pubitemid 40215007)
6. Mirochnick M, Best BM, Stek AM, et al. Atazanavir Pharmacokinetics With and Without Tenofovir during Pregnancy. J Acquir Immune Defic Syndr. 2011;56: 412-419.
7. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS. 2006;20: 1931-1939. (Pubitemid 44427610)
8. Sustiva (Efavirenz) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2007.
9. The Division of AIDS (DAIDS). Standardized toxicity table for grading severity of adult adverse experiences. Available at: http: //rcc.tech-resintl. com. Accessed August 3, 1997.
10. Holland DT, DiFrancesco R, Stone J, et al. Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother. 2004;48: 824-831. (Pubitemid 38280331)
11. la PorteBack C, Back D, Blaschke T, et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antivir Ther. 2006;3: 4-14.
12. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet. 2004;43: 1071-1087. (Pubitemid 40013177)
13. Capparelli EV, Aweeka F, Hitti J, et al. Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med. 2008;9: 214-220. (Pubitemid 351467794)
14. Lamorde M, Byakika-Kibwika P, Okaba-Kayom V, et al. Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women. J Acquir Immune Defic Syndr. 2010;55: 345-350.
15. Izurieta P, Kakuda TN, Feys C, et al. Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women. HIV Med. 2011;12: 257-258.
16. Cressey TR, Lallemant M. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update. Infect Genet Evol. 2007;7: 333-342. (Pubitemid 46187499)
17. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Aids. 2004;18: 2391-2400. (Pubitemid 40065906)
18. Chantarangsu S, Cressey TR, Mahasirimongkol S, et al. Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women. J Antimicrob Chemother. 2009;64: 1265-1273.
19. The antiretroviral pregnancy registry. Interim report: 01 January 1998 to 31 January 2010. Available at: http: //wwwapregistrycom/forms/interim- reportpdf. Accessed August 15, 2011.
20. Ford N, Mofenson L, Kranzer K, et al. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS. 2010;24: 1461-1470.
21. Atripla [package insert]. Foster City, CA: Bristol-Myers Squibb & Gilead Sciences, LLC; 2011. Available at: http: //www.gilead.ca/pdf/ca/atripla- pm-english.pdf. Accessed August 15, 2011.
22. Moisan A, Desnoyer A, Bourgeois-Moine A, et al. Placental transfer of antiretroviral drugs in HIV-infected women: a retrospective study from 2002 to 2009. Presented at: 11th International Workshop on Clinical Pharmacology of HIV Therapy. April 7-9, 2010; Sorrento, Italy.
23. Cressey TR, Jourdain G, Rawangban B, et al. Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. AIDS. 2010;24: 2193-2200.
24. Ramautarsing RA, van der Lugt J, Gorowara M, et al. Thai HIV- 1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy. AIDS. 2011;25: 1299-1303.